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Introduction
Tobacco exposure is an established risk factor for sev-
eral cancers including lung carcinoma [1]. The devel-
opment of tobacco related malignancies appears to
depend on the duration and intensity of exposure to the
carcinogen [2] as well as genetic susceptibility [1,2].
The presence of genetic susceptibilities is confirmed
by the higher incidence of cancer in first-degree rela-
tives of patients with lung carcinoma [3] and the inter-
racial differences in the susceptibility to the carcino-
genic effects of tobacco [4]. Understanding the mech-
anisms of susceptibility will facilitate the prevention
and early detection of lung carcinoma.
The carcinogen metabolizing enzymes are involved
in the activation and deactivation of diverse chemical
carcinogens. Inter-individual and inter-racial varia-
tions in the expression of these enzymes in target tis-
sues may explain the differences in susceptibility
observed in clinical and epidemiological studies [5]. 
Potent carcinogens like polycyclic aromatic hydro-
carbons (PAHs), aromatic and heterocyclic amines
present in the diet, occupational and environmental
exposures induce tumors, following metabolic activa-
tion to reactive derivatives that form DNA adducts [6]. 
The PAHs activated by hydroxylation can be detox-
ified via glutathione conjugation by glutathione-S-
transferases (GSTs), which are phase-II metabolizing
isoenzymes. They facilitate clearance of endogenous
hydrophobic compounds such as hormones, steroids,
haem, bilirubin, and bile acids. Furthermore, they are
essential for metabolism of environmental carcino-
gens, drugs and pesticides by catalyzing the conjuga-
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tion of reactive chemical intermediates to soluble glu-
tathione conjugates. Seven classes of cytosolic GSTs
are recognized in mammalian tissues: alpha (GSTA),
mu (GSTM), pi (GSTP), omega (GSTO), sigma
(GSTS), theta (GSTT), and zeta (GSTZ) [7]. 
It was demonstrated that the GST detoxification
capacity is tissue dependent in rodents [8]. Apart from
the liver enzymes, most of the GST enzymes were also
found in extrahepatic tissues such as muscle, testis,
lung, brain, heart, blood and upper areodigestive
mucosa [9-11]. The fact that most of the xenobiotic
enzymes are expressed in a tissue-specific manner
leads to great differences in the activation and inacti-
vation of xenobiotics in different tissues.
In lung carcinoma, polymorphic GST isoenzymes
may play a role in tumorigenesis and resistance to
chemotherapy [12]. The GSTP is the most widely dis-
tributed isoenzyme [13]. It is expressed as a major
form in many organs, such as lung, esophagus, kidney,
and placenta [14]. Furthermore, expression of GSTP is
elevated in many tumors relative to their matched nor-
mal tissue [15]. GSTP has been shown to be an useful
marker for differential diagnosis in histopathology and
intrinsic sensitivity to anticancer drugs of lung cancer
[16].
Carcinogens and their metabolites result in malig-
nant transformation through mutations altering the
function of critical proto-oncogenes or tumor suppres-
sor genes. The expression rate of altered p53 tumor
suppressor gene was relatively high in small cell lung
cancer (SCLC) without any prognostic significance
[17]. 
The aim of this study was to evaluate the effects of
the expression of GSTA (A), mu (M4), pi (P) and theta
(T1) enzymes and p53 in normal and neoplastic lung
tissue from the same patient group on the development
of non-small cell lung carcinoma (NSCLC) and dis-
cuss their role in conjunction with known lung cancer
prognostic factors.
Material and methods
Patients. For immunohistochemical studies, tissues from 50
patients with NSCLC at the Sanatoryum Education and Research
Hospital were used. For all patients, tumor stage, smoking status,
tumor grade status were available. Operation material was exam-
ined macroscopically by a pathologist in each case and two tissue
samples were taken: one from the tumor tissue and one from the
macroscopically normal tissue peripheral to the tumor tissue. 
Immunohistochemical staining. The tissues were fixed in 10%
buffered formalin and embedded in paraffin blocks. Sections that
were 4 μm thick were cut, and one section was stained with H+E
to observe the tissue morphology and tumor grade. For immuno-
histochemistry, endogenous peroxidase activity was blocked by
incubating the sections in 1% hydrogen peroxide (v/v) in methanol
for 10 minutes at room temperature (RT). The sections were sub-
sequently washed in distilled water for 5 minutes and antigen
retrieval was performed for 3 minutes using 0.01M citrate buffer
(pH 6.0) in a domestic pressure cooker. The sections were trans-
ferred in 0.05M Tris-HCl (pH 7.6) containing 0.15M sodium chlo-
ride (TBS). After washing in water, the sections were incubated at
RT for 30 minutes with either normal swine serum (for anti-GSTA,
GSTP and p53) (1:20) or normal goat serum (for anti-GSTT1 and
GSTM4) (1:20) diluted in TBS to block nonspecific binding. The
sections were then covered with the primary antibodies diluted
1:100 for anti-GSTA, GSTP and p53; 1:50 for anti-GSTM4 and
1:500 for anti-GSTT1 in TBS at 4°C overnight (Monoclonal anti-
body against GSTT1 was from Labas International Limited, Esto-
nia. Polyclonal antibodies against GSTA, GSTM4, GSTP and p53
raised in rabbit were purchased from Lab Vision Thermo Scientif-
ic, USA.) After washing in TBS (15 minutes) sections were incu-
bated at RT for 1 hour with secondary antibody (swine-anti-rabbit
Ig-biotinylated for anti-GSTA, GSTP and p53 or goat-anti-rabbit
Ig-biotinylated for anti-GSTT1 and GSTM4) at a dilution of 1:100.
Then, it was followed by treatment with avidin-biotin peroxidase
complex (Dakopatts, Denmark). Diaminobenzidine was used to
visualize peroxidase activity in the tissues. Nuclei were lightly
counterstained with hematoxyline and then the sections were dehy-
drated and mounted. Both positive and negative controls were
included in each run. Positive controls consisted of sections of nor-
mal human liver for GSTA, GSTM4 and GSTT1 and normal
human small intestine for GSTP. TBS was used in place of the pri-
mary antibody for negative controls.
Immunohistochemically stained sections were examined by
light microscopy without knowing the clinical information of the
patients and the distribution, localization and the characteristics of
immunostaining were recorded. Brown colour in cytoplasm and/or
nucleus of the epithelial cells was evaluated as positive staining.
Scoring was performed by both observers without knowledge of
patient data. Scoring differences between observers were resolved
by consensus. For each GST antibody, one feature to describe the
immunoreactions was recorded using a semi quantitative scale: the
relative number of positive cancer cells (0% (-), <10% (1+), 11%
to 50% (2+), or >50% (3+)). For p53 staining, the relative number
of positive cancer cells (<10%, to >10%) and positive and negative
tumor nuclear staining were evaluated.
Statistical analysis. For each isoenzyme, staining scores in inva-
sive and normal epithelium were compared statistically. The rela-
tionships between expression of the GST isoenzymes and p53 in
normal and tumor tissue were examined by student T test. Clinico-
pathological data (tumor stage, tumor grade, and smoking status)
were also examined by Spearman Ranks tests for checking that the
relationships were significant or not. 
Results
Fifty examples of NSCLC and normal from the sur-
rounding lung tissue were examined from 50 patients
(Table 1-2). 
GSTA expression was stronger in tumor epithelium
than normal epithelium in lung cancers (Table 1,
p<0.05). The 58% of the negative GSTA expression
was normal epithelium and 70% of tumors were con-
sidered to have GSTA expression (Table 1). Fig. 1
showed that strong nuclear and cytoplasmic staining
with GSTA was observed in lung adenocarcinoma
cells.
Similarly, GSTT1 and GSTM4 expressions were
higher in tumor epithelium than normal epithelium in
human lung cancer. There were statistically significant
differences in GSTT1 and GSTM4 expressions
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between normal and tumor epithelium (p<0.05) (Table
1). The 29% of the negative GSTM4 expression was
normal epithelium, but 66% of tumors were consid-
ered to have strong GSTM4 expression (Fig. 2). Simi-
larly, 57% of the negative GSTT1 expression was nor-
mal epithelium, but 41% of tumors were considered to
have moderate GSTT1 expression (Table 1).
45% of the moderate GSTP expression were tumor
epithelium (Fig. 3) and 57% of the normal were con-
sidered to have weak GSTP expression (p<0.05). Thus,
the stronger GSTP was observed in tumor epithelium
than normal epithelium in human lung cancers. The
67% of the negative p53 expression was normal
epithelium, and 47% of the tumor was considered to
have positive p53 expression (p>0.05) (Fig. 4). 
Histologic grade of the tumors was determined on
H+E stained slides. The 22 cases were grade I, 20
cases were grade II, and 8 cases were grade III inva-
sive NSCLCs. Nineteen patients were in stage 1, 18 in
stage 2, and 13 in stage 3. 
When the clinical and pathologic characteristic of
the lung cancers with the levels of GSTA, GSTP,
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Table 1. Relationship between expressions of GSTA, GSTP, GSTT1, GSTM4 and p53 by normal epithelium and tumor epithelium in
NSCLC according to the relative number of positive cancer cells. 
Correlation is significant at the p<0.05 level (2-tailed). Asym.Sig: (p)
Correlation is significant at the p<0.05 level (2-tailed). Asym.Sig: (p)
Table 2. Relationship between GSTA, GSTP, GSTT1, GSTM4 and p53 expressions with clinical and pathologic characteristics in
NSCLC. 
GSTM4, GSTT1 and p53 expressions were correlated
separately, there were no significant associations
between tumor stage, smoking status and tumor grade
and GSTs and p53 expressions in tumor tissue
(p>0.05) (Table 2).
Discussion
Lung carcinoma remains a worldwide public health
issue of immense proportions. In 2004, carcinomas of
the lung and bronchus are expected to continue to
account for the highest proportion of cancer deaths in
the United States (160,440 deaths or 28.5%), more
than the estimated total number of deaths due to carci-
nomas of the breast, prostate, colon and rectum com-
bined [18]. Approximately 80% of lung carcinomas
will have non-small cell carcinoma histology [19].
Smoking tobacco has been implicated as the main
causative factor in development of lung cancer, and
only about 1% of lung cancer occurs in nonsmokers. 
Polycyclic aromatic hydrocarbons, aromatic
amines, and nitroso compounds are among the car-
cinogens that have been identified in tobacco smoke
[20]. The cytochrome P450 (CYP) enzymes oxidize
these compounds yielding reactive epoxide intermedi-
ates, which can covalently bind and alter DNA struc-
ture [21]. GST enzymes catalyze glutathione conjuga-
tion of these intermediates, thereby decreasing their
DNA damaging effects [22]. Variations in the expres-
sion of CYPs and GST could potentially explain the
observed difference in vulnerability to the carcino-
genic effects of tobacco. Previous studies have demon-
strated the expression of CYPs and GST in normal
squamous epithelium of the lung [23]. CYP and GST
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Fig. 1. This case of adenocarcinoma had strong nuclear and cyto-
plasmic staining with GSTA in more than 90% of the tumor
(GSTA, original magnification ×400).
Fig. 3. An adenocarcinoma cells show moderate nuclear and cyto-
plasmic staining for GSTP. (GSTP, original magnification ×400)
Fig. 2. A case of squamous cell lung carcinoma had moderate
nuclear and cytoplasmic staining with GSTM4 in more than 90%
of the tumor cells (GSTM4, original magnification ×100).
Fig. 4. This case of squamous cell lung carcinoma cells had strong
nuclear staining in more than 80% of the tumor. (p53, original
magnification ×400)
expression varies in different tissues [24,15]. Tissue
metabolism of carcinogens by these locally expressed
enzymes may be a more important determinant of car-
cinogenesis than metabolism in the more distant
organs such as the liver. Several studies assessed the
risk of lung cancer in relation to GST genotypes [25-
27]. However, inter-individual variations in the
expression and activity of GST are dependent on geno-
typic as well as post-transcriptional factors, which may
be tissue specific [28-30]. Therefore, the most direct
method to evaluate the effects of GST on the carcino-
genic effects of tobacco is to evaluate enzyme expres-
sion in the tissue of interest.
To our knowledge, this study represents the first
comprehensive description of the four classes of GSTs
in normal and tumor human lung. In this study, we
observed stronger staining intensity for GSTP, GSTA,
GSTM4 and GSTT1 in tumor epithelial cells when
compared with normal cells (P<0.05). However, there
was no difference in staining intensity for p53 between
tumor epithelium and normal epithelium cells (Table
1, p>0.05). Cancer cells reveal multiple genetic alter-
ations resulting in morphological and functional dif-
ferences from the normal cells. Tumor cells may
change some of their functions (e.g. expression of
some proteins) in the malignant transformation
process. It can be speculated that higher level of GST
expression in the tumor cells can be a result of this
transformation. The current immunohistochemical
investigation revealed appreciable expression of GSTP
in 96% of NSCLC (Table 1).This value was slightly
same or higher those reported earlier for carcinomas of
the uterine cervix (96%) [31] and colorectum (88%)
[32]. In a more extended study, Saydam and cowork-
ers [33] and Hida and coworkers [34] reported signifi-
cantly higher GST enzyme activity levels and plasma
GSTP values in human lung cancers as compared with
control tissues. 
Arai and coworkers [35] using immunohistochem-
istry, detected GSTP in 56.2% of non-small cell lung
cancer. Nie and coworkers [16] assessed GSTs isoen-
zymes composition by immunohistochemical tech-
nique. They found that the total positive rates of GSTP
and GSTM4 in 89 cases of non-SCLC were 75.3% and
9.7% respectively. Among them squamous cell carci-
noma were stained positively for GSTP in 93.5%, and
GSTM4 in 6.5%, while adenocarcinoma were in
69.7%, and 6.1% respectively. 
As p53 is the most commonly mutated gene in
human cancer, including lung squamous cell carcino-
ma, it has attracted a great deal of interest as a prog-
nostic factor, diagnostic tool and therapeutic target
[17]. Recent studies using immunohistochemical stain-
ing following antigen retrieval investigated the expres-
sion of p53 in 45 patients with non-small cell lung car-
cinomas and found that 40% of the tumors demon-
strated positive of p53. However, p53 positive was not
predictive as a prognostic factor for clinical outcome
[36]. We have also used immunohistochemical stain-
ing following antigen retrieval techniques to investi-
gate the expression of p53 in lung squamous cell car-
cinomas and adenocarcinoma, and found that p53 was
expressed in 47% of NSCLC, but no statistically sig-
nificant difference between normal and tumor tissue
for p53 expression was observed. 
In this study, there were no correlation between
GSTs and p53 expressions and known prognostic indi-
cators. Allen and coworkers [37] have examined the
relationship between GSTP overexpression and histo-
logical stage in squamous cell lung carcinomas. They
have reported that nuclear staining with GSTP in
greater than 10% of the cells was closely associated
with decreased survival (P=0.02) in stage I and II
squamous cell lung carcinomas (n=40). 
We observed that there was a non-significant rela-
tionship between GSTs, p53 expressions and tumor
grade, and that there was a non-significant relationship
between GSTs, p53 expressions and tumor stage. 
Environmental carcinogen besides cigarette could
induce lung cancer. Our findings indicated a non-sig-
nificant relationship between GSTs, p53 expressions
and smoking status of lung cancer patients. 
The number of lung cancer patients in this analysis
can be considered small. Future studies with substan-
tially larger numbers of lung cancer patients will be
needed to examine prospectively for the possible rela-
tionship between GST expression and prognostic fac-
tors.
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